COTA and Panalgo Q&A
COTA Spokesperson: C.K. Wang, Chief Medical Officer Panalgo Spokesperson: Meg Richards, PhD, MPH, Executive Director of Scientific Strategy Abbreviated answers Q: What is the value of real-world data for accurate healthcare analytics – what can be learned from high-quality electronic health record data? Meg: Real-world data (RWD), particularly those derived from high-quality electronic health records […]
Panalgo Partners with COTA, Adding Oncology Data to Its Industry-Leading IHD Platform
Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, has announced its partnership with COTA, an organization that brings clarity to cancer care with a precise, patient-first approach based on real-world data (RWD). BOSTON, Sept. 9, 2024 /PRNewswire-PRWeb/ — Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, has announced its partnership with COTA, an organization that […]
COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine
New York — COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Unlocking Insights from Electronic Health Records (EHRs) Electronic health records […]
3 traits to look for in an oncology real-world data partner
Before raw, real-world data (RWD) can be transformed into actionable insights, it has to go through a number of different processes, from aggregation and abstraction to standardization and careful curation.
For the hematology community, AI and RWD are top of mind
A huge number of new breakthroughs in drug development, treatment guidelines, and decision support technologies occur every day to treat blood cancers.
LLMs aren’t good enough at diagnostics yet. What will it take to get them there?
Large language models (LLMs) are the foundation of highly hyped generative AI tools like Chat-GPT and Google Bard.
What’s in store for 2024? Generative AI, digital health funding, and real-world data
To ring in the new year, we asked COTA’s leadership team about their top predictions for 2024 in the oncology, real-world data, and life sciences spaces.
Women in Health Innovation: Deloitte x COTA blog series
In our blog series with Deloitte, we have written extensively about the benefits of using Real World Data to enhance clinical trials and accelerate research into new therapies for a variety of conditions.
COTA and Aetion partner to expand access to real-world data for oncology research
This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.
Overcoming challenges to integrating biomarker data into clinical trials
Life sciences researchers and oncologists are learning more about cancer pathogenesis and treatment every day, largely thanks to explosive innovation in the world of biomarkers.
